3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
29
Triple Negative Breast Neoplasms
9
Sarcoma
5
Neoplasm Metastasis
5
Liposarcoma
3
Inflammatory Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Leiomyosarcoma
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Refractory Solid Tumors
1
Recurrence
1
Metastatic HER2-positive Breast Cancer
1
Ketosis
1
Inoperable Locally Advanced HER2-Negative Breast Cancer
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
HR+HER2- Breast Cancer
1
HER2-negative Metastatic Breast Cancer
1
HER2-low Breast Cancer
1
Fludzoparib" and Anti-angiogenic
1
Colorectal Neoplasms
1
Brest Cancer
1
Brain Neoplasms
1
Advanced Breast Cancer
1
Interventions
Methylprednisolone
3
Social Determinants of Health
2
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pegaspargase
1
Vincristine
1
Temozolomide
1
Radiotherapy
1
Prednisone
1
Prednisolone
1
Pharmaceutical Services
1
Methylprednisolone Hemisuccinate
1
Methotrexate
1
Mercaptopurine
1
Leucovorin
1
Irinotecan
1
Infliximab
1
Hydrocortisone
1
Fecal Microbiota Transplantation
1
Etoposide
1
Drug Therapy
1
Doxorubicin
1
Dexrazoxane
1
Dexamethasone
1
Cytarabine
1
Cyclophosphamide
1
Cefixime
1
CTLA-4 Antigen
1
Asparaginase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Drug-Related Side Effects and Adverse Reactions
×
eribulin
×
1 year
×
Clear all
No trials found.